News

Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove LDL-C, or "bad" cholesterol, from the blood. Elevated LDL-C is

The study findings, which are being presented in a late-breaking oral presentation at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, confirmed the antiretroviral

Neither the R&D goal that generated the milestone payment nor the amount were disclosed. The MvfR inhibitor program targets mechanisms of virulence and persistence in Pseudomonas and other

Iluvien is Alimera’s sustained release intravitreal implant designed for the treatment of diabetic macular edema (DME). Currently, Iluvien is not approved for sale in Canada. Iluvien (fluocinolone acetonide

The company said that BMS-663068 is an oral prodrug of the molecule BMS-626529 and first-in-class HIV-1 attachment inhibitor. BMS-663068 is designed to work differently than entry inhibitors, a

Dosing in this multi-center, open-label, dose-escalation trial has been carried out by the University of Virginia School of Medicine. The company is conducting the trial in collaboration with

The company said that ISIS-HTT is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production

MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens. The company has developed the oral formulation of

The study will use Forge’s expertise and intellectual property in the field of metalloprotein inhibitor discovery, while the company will receive funding support from JRD. Forge Therapeutics CEO